Page last updated: 2024-12-08
sq 14,603
Description
2-benzyl-3-mercaptopropanoic acid: structure; carboxypeptidase inhibitor [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|
| PubMed CID | 194327 |
| CHEMBL ID | 58957 |
| SCHEMBL ID | 1559014 |
| MeSH ID | M0361220 |
Synonyms (17)
| Synonym |
|---|
| 69734-01-6 |
| CHEMBL58957 , |
| sq-14603 |
| 2-benzyl-3-sulfanylpropanoic acid |
| 2-benzyl-3-mercapto-propionic acid |
| 2-mercaptomethyl-3-phenyl-propionic acid |
| bdbm50109593 |
| sq-14,603 |
| benzenepropanoic acid, alpha-(mercaptomethyl)-, (+-)- |
| sq14,603 |
| 2-benzyl-3-mercaptopropanoic acid |
| sq 14,603 |
| SCHEMBL1559014 |
| 2-mercaptomethyl-3-phenylpropionic acid |
| ZUEBVBPVXLQMQR-UHFFFAOYSA-N |
| 81110-55-6 |
| DTXSID80989900 |
Research Excerpts
Bioavailability
| Excerpt | Reference | Relevance |
|---|
| " The most potent thiol-based inhibitor, 2-(3-mercaptopropyl)pentanedioic acid (IC(50) = 90 nM), was found to be orally bioavailable in rats and exhibited efficacy in an animal model of neuropathic pain following oral administration." | ( Synthesis and biological evaluation of thiol-based inhibitors of glutamate carboxypeptidase II: discovery of an orally active GCP II inhibitor.
Burak, E; Delahanty, G; Grella, BS; Jackson, PF; Ko, YS; Li, W; Limsakun, T; Liu, Q; Maclin, KM; Majer, P; Poláková, J; Rojas, C; Shaffer, KA; Slusher, BS; Stoermer, D; Tsukamoto, T; Vitharana, D; Wang, EY; Wozniak, KM; Zakrzewski, A, 2003) | 0.32 |
Protein Targets (3)
Inhibition Measurements
Biological Processes (6)
Molecular Functions (9)
Ceullar Components (6)
Bioassays (4)
| Assay ID | Title | Year | Journal | Article |
|---|
| AID304048 | Selectivity for bovine pancreatic carboxypeptidase A over porcine pancreatic carboxypeptidase B | 2007 | Journal of medicinal chemistry, Nov-29, Volume: 50, Issue:24
| Discovery of potent & selective inhibitors of activated thrombin-activatable fibrinolysis inhibitor for the treatment of thrombosis. |
| AID304047 | Inhibition of bovine pancreatic carboxypeptidase A | 2007 | Journal of medicinal chemistry, Nov-29, Volume: 50, Issue:24
| Discovery of potent & selective inhibitors of activated thrombin-activatable fibrinolysis inhibitor for the treatment of thrombosis. |
| AID48474 | Inhibition of bovine carboxypeptidase A (CPA) using hippuryl-L-phenylalanine (Hipp-L-Phe) as a substrate. | 2002 | Journal of medicinal chemistry, Feb-14, Volume: 45, Issue:4
| Cysteine derivatives as inhibitors for carboxypeptidase A: synthesis and structure-activity relationships. |
| AID74532 | In vitro inhibitory activity against glutamate carboxypeptidase II (GCP II) using N-acetyl-L-aspartyl-[3H]L-glutamate as a substrate | 2003 | Journal of medicinal chemistry, May-08, Volume: 46, Issue:10
| Synthesis and biological evaluation of thiol-based inhibitors of glutamate carboxypeptidase II: discovery of an orally active GCP II inhibitor. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Research
Studies (6)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|
| pre-1990 | 2 (33.33) | 18.7374 |
| 1990's | 1 (16.67) | 18.2507 |
| 2000's | 3 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 12.67
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| Metric | This Compound (vs All) |
|---|
| Research Demand Index | 12.67 (24.57) | | Research Supply Index | 1.95 (2.92) | | Research Growth Index | 4.62 (4.65) | | Search Engine Demand Index | 0.00 (26.88) | | Search Engine Supply Index | 0.00 (0.95) |
| |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 6 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |